Abstract Body

HIV prevention has been revolutionized by biomedical advances in pre-exposure prophylaxis (PrEP) which has changed the trajectory of the HIV epidemic in areas with high uptake. PrEP with daily oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was first shown to be effective for HIV prevention in the iPrEx study more than a decade ago, however despite high effectiveness in subsequent trials, demonstration projects, and clinical studies implementation has been challenged by structural, social, and individual barriers in many jurisdictions. In the US, only 7% of those who may benefit from PrEP have been prescribed PrEP per estimates from the Centers for Disease Control and Prevention. Adherence and persistence remain the ‘Achilles heel’ of daily oral PrEP and new long acting PrEP options, such as bimonthly injections of Cabotegravir long-acting (CAB-LA) which was recently approved by the US Food and Drug Administration in 2021, provides a PrEP option without daily adherence. However, CAB-LA does require adherence to an increased visit schedule and clinical support for administering and tracking injections. New products in development such as Islatravir (as a monthly oral pill or implant), and Lenacapavir (a semi-annual subcutaneous injection) would allow less frequent clinical visits, and potentially require fewer clinical resources. These new PrEP options will provide an important element initially missing from our biomedical toolbox – choice. Using lessons learned from contraception, implementation will need to include low-barrier access such as drop-in and non-traditional hours; an expanded pool of providers to increase service availability; clinician and clinical staff education and training; and policies that help lower out-of-pocket costs for patients. The implementation of these types of strategies will be required to provide an authentic choice of current and burgeoning HIV prevention options.